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Introduction
Progress in developing new treatments for urothelial carcinoma (UC) has been stagnant for 
more than 20 years. A paradigm shift is needed to advance treatment for UC. For patients 
with advanced disease and in whom chemotherapy regimens have failed, a variety of single-
agent or combination therapies, including molecularly targeted agents, have yielded modest 
response rates and poor survival durations.1,2 Although immunotherapy portends new 
promise, vinflunine is the only approved drug in Europe (European Medicines Agency) for 
progressive UC after platinum-based therapy, and the US Food and Drug Administration has 
not approved any agent.3 Advancements in genomic profiling of UC, mainly through The 
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Cancer Genome Atlas (TCGA) project, recently made exceptional steps forward to uncover 
pertinent information on the underlying UC biology and potentially druggable pathways.4 
The strategy to molecularly characterize patients who had achieved an extreme response to 
targeted drugs recently helped investigators to put known relevant alterations into the context 
of a clinical benefit from those compounds.5-7 This paradigm might best apply to anti-
angiogenics, for which a proportion of approximately 5% to 10% complete or sustained 
responders has been reported for therapies including pazopanib.8,9
Case Report
Patients and Methods
Forty-one patients with UC in whom 1 or multiple chemotherapy regimens had failed were 
enrolled in an open label, phase II trial of pazopanib,9 a multikinase inhibitor with distinct 
antiangiogenic activity targeting various transmembrane receptors, including vascular 
epidermal growth factor receptor 1-3, platelet-derived growth factor receptor (PDGFR) α 
and β, c-stem cell growth factor receptor (KIT), and fibroblast growth factor receptor 
(FGFR). Despite a promising 17% response rate, progression-free and overall survival were 
poor. Nevertheless, 2 sustained partial responses (PRs) were reported at long term follow-
up.10 On the basis of the availability of tumor samples and the quality of response, we 
selected 3 patients for molecular interrogation. Patient 1 had achieved a 32-month PR 
(Figure 1 and Supplemental Table 1 in the online version) in the third-line meta-static 
setting, patient 2 had stable disease of 2.7 months in the fourth-line setting, and patient 3 
experienced progressive disease during second-line treatment.
DNA was extracted from formalin-fixed paraffin-embedded tumor and matched normal 
blood samples of each patient, and then profiled using the custom hybridization capture 
panel Memorial Sloan Kettering (MSK)-Integrated Mutation Profiling of Actionable Cancer 
Targets (IMPACT) assay for the targeted sequencing of all exons of 341 cancer-relevant 
genes. We analyzed the presence of somatic variants, small insertions and/or deletions, and 
copy number alterations. The MSK-IMPACT was analytically validated for sensitivity, 
specificity, reproducibility, and was able to detect variants with 10% frequency at 98% 
power (α = 0.05) when coverage was at least 100×.11 The study was approved by the 
internal review board and ethics committee of the Fondazione IRCCS Istituto Nazionale dei 
Tumori, Milano.
Results
The mean coverage of the targeted regions in each patient's tumor ranged from 455 to 722× 
(Supplemental Table 2 in the online version). In the 3 patients, we found a total of 95 
significant non-synonymous single nucleotide variants (SNVs), splicing events (SEs), 
frameshift deletions (FDs) and insertions (FI), stop gain SNVs (sg.SNVs), and upstream 
mutations (Supplemental Table 3 in the online version). Among these alterations, 31 were 
truncating mutations (FD, FI, sg.SNV, and SE) and 24 were registered in the Catalogue Of 
Somatic Mutations in Cancer database and were thus considered “likely deleterious” (LD) 
and “recurrently altered” (RA), respectively; 7 alterations were LD and RA (detailed in 
Supplemental Figure 1 and Supplemental Table 4 in the online version). Further-more, 
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patient 1 harbored the most alterations with 74 somatic events (55 genes), 34 of which were 
RA and/or LD (involving 25 genes). More in detail, patient 1 harbored an ERBB3 RA 
mutation (R475W), an neurofibromin 1 truncation and alterations in chromatin-remodeling 
genes reported at high frequency in TCGA, such as multiple lysine (K)-specific 
methyltransferase 2D and CREB binding protein mutations, an E1A binding protein p300 
frameshift alteration, and a lysine (K)-specific methyltransferase 2C point mutation. Finally, 
patient 1 had 2 LD mutations in mouse DNA polymerase epsilon, which is known to be 
involved in DNA repair and chromosomal DNA replication.
Patient 2 also had an AT rich interactive domain 1A frameshift and a lysine (K)-specific 
methyltransferase 2A point mutation.
Mutations of mammalian target of rapamycin (mTOR) and erb-b2 receptor tyrosine kinase 2 
(ERBB2) occurred at different sites in both responders; in particular, in patient 2 the mTOR 
mutation (D928N) was RA (COSM3471344) and the ERBB2 mutation (S310F) is a hotspot 
driver mutation in UC that is known to be activating.12 Importantly, we found a significant 
copy number amplification (CNA) of epidermal growth factor receptor (EGFR) with a fold-
change of 17 in patient 1 (Figure 2 and Supplemental Table 5 in the online version).
The refractory case (patient 3) presented a deletion in cyclin-dependent kinase inhibitor-2A 
(Figure 2 and Supplemental Table 5 in the online version) and showed mutations in lysine 
(K)-specific demethylase 6A (KDM6A), stromal antigen 2 (STAG2), FGFR3 (S249C) and 
an H1047R phosphatidylinositol-4, 5-Bisphosphate 3-Kinase, catalytic Subunit alpha 
(PIK3CA), which is an activating mutation, occurs in a hotspot in the catalytic domain, and 
induces the growth factor-independent proliferation.12 Interestingly, in patient 3 we found 
the FGFR3 mutation S249C, which is a known activating mutation and the most frequently 
observed mutation in the gene. Interestingly, the same activating mutation, associated with 
gene amplification, has been reported in a patient who had achieved a significant response to 
pazopanib in another study.13
Many of the mutations found in the 3 patients were validated (www.cbioportal.org; see 
Supplemental Table 4 in the online version)4 or were predicted to have a deleterious effect 
on protein function using the PolyPhen-2 algorithm (http://www.broadinstitute.org/
oncotator).
When considering the mutations specific for each patient or common among them 
(Supplemental Table 6 in the online version), we observed that in the responding patients 3 
genes (mTOR, FAT atypical cadherin 1, and ERBB2, and only the latter 2 considering LD 
mutations) were mutated, an 8 genes (nuclear factor erythroid 2-like 2, PIK3CA, FGFR3, 
polo-like kinase 2, folliculin, SWI/SNF related, matrix associated, actin dependent regulator 
of chromatin, subfamily A, member 4, KDM6A, and STAG2; 7 LD) were specifically 
mutated in the nonresponding patient. The most altered pathways of the analyzed patients 
are summarized in Supplemental Table 7 in the online version. In particular, the chromatin-
remodeling genes were the most frequently altered, as with previous reports.4
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Discussion
EGFR, ERBB2, and pazopanib targets (PDGFR, KIT, and kinase insert domain receptor) 
share the same signaling pathways, involving the RAS-RAF and the phosphoinositide 3-
kinase (PI3K)-AKT pathways. These pathways were found to be heavily altered, especially 
at the receptor level, in all 3 patients, although for many identified alterations there were no 
conclusive indications about their biological effect. The most relevant alterations (LD and/or 
RA) included the EGFR CNA in patient 1, mutations in ERBB2 in both responders, and in 
FGFR3 and phosphoinositide-3-kinase, catalytic, alpha polypeptide in the non-responding 
patient. These alterations might be putative biomarkers of sensitivity to pazopanib.
To summarize, many issues affect the efforts to clinically contextualize the molecular 
alterations we have detected, and of course a number of biases should be acknowledged. 
First, and most important, it is unknown whether these molecular alterations are linked to 
drug response or whether they represent prognostic biomarkers independent of the treatment 
delivered. Second, the increasing molecular characterization of extreme re-sponders to 
targeted agents is also raising concerns about the clinical relevance of specific alterations 
(FGFR3 mutation and response to pazopanib is paradigmatic). Third, the mechanisms 
underlying the activity of multitargeted tyrosine kinase inhibitors like pazopanib and the role 
of specific mutations have not been definitively elucidated. An important finding in our 
study is the association of the burden of molecular alterations with the sustained response to 
pazopanib. In this huge amount of complexity, the role of mutations in multiple epigenetic 
regulatory genes deserves special attention, because inactivating alterations in some of these 
genes might lead to sensitivity to histone deacetylase inhibitors, and a clinical trial with one 
of these compounds (ie, mocetinostat) is currently under way (NCT02236195).
Conclusion
The functional interpretation of the altered network dynamics during pazopanib treatment 
and the possible EGFR-, ERBB2-, FGFR3-, or PI3K-targeting with sequences or 
combinations of antiangiogenic drugs and in patient-enriched study designs might deserve 
further investigation.
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Refer to Web version on PubMed Central for supplementary material.
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Clinical Practice Points
• The mechanisms that underlie the therapeutic response of urothelial 
carcinoma (UC) to targeted drugs remain largely unclear.
• We sequenced archival tissue from 3 outlier patients who had been 
treated with pazopanib after chemotherapy treatment had failed: a 32-
month partial response (patient 1) in the third-line setting, a 3-month 
stable disease (patient 2) in the fourth-line setting, and a primary 
refractory case (patient 3). Tumor and matching germline DNA were 
sequenced using a targeted next-generation deep sequencing assay to 
identify somatic variants, small insertions or deletions, and copy 
number alterations.
• In responding patients we found a significant focal epidermal growth 
factor receptor copy number amplification and an erb-b2 receptor 
tyrosine kinase 2 (ERBB2) S310F activating mutation. ERBB2 
mutations occurred at different sites in patients 1 and 2, and multiple 
alterations in chromatin-remodeling genes.
• Patient 3 showed mutations in fibroblast growth factor receptor 3 
(FGFR3) and phosphoinositide-3-kinase, catalytic, alpha polypeptide, 
which could attenuate response to pazopanib.
• In summary, we reported peculiar genomic alterations that might be 
putative variants of differential sensitivity to pazopanib in advanced 
UC.
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Figure 1. 
Computed Tomography Scans Showing the Best Response in (A) Retroperitoneal and (B) 
Hepatic Disease of Patient 1. Left Panels: Baseline Examination; Right Panels: Best 
Response (Achieved After 4 Weeks of Pazopanib Treatment)
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Figure 2. 
Copy Number Alterations in Patients 1 and 3 (Top and Bottom Panel, Respectively). Each 
Dot Represents a Target Exon. The Genomic Regions Affected by Significant Copy Number 
Amplification (EGFR in Patient 1) and Deletion (CDKN2A in Patient 3) Are Highlighted in 
Red
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